0.628

0.89% -0.00562

After Hours: .62 -0.008 -1.27%

Matinas Biopharma Holdings Inc (MTNB)

Overview News Price History Discussions Forecast

Matinas Biopharma Holdings Inc stock is traded at $0.628, with a volume of 29,622. It is down -0.89% in the last 24 hours and down -20.41% over the past month. Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Previous Close:

$0.6336

Open:

$0.615

24h Volume:

29,622

Relative Volume:

0.20

Market Cap:

$4.02M

Revenue:

$1.10M

Net Income/Loss:

$-11.23M

P/E Ratio:

-0.3101

EPS:

-2.025

Net Cash Flow:

$-6.61M

1W Performance:

-5.42%

1M Performance:

-20.41%

6M Performance:

+5.00%

1Y Performance:

-31.53%

1-Day Range:

$0.615

$0.6395

1-Week Range:

$0.612

$0.6735

52-Week Range:

$0.48

$3.09

Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile

Name

Matinas Biopharma Holdings Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

908-443-1860

Address

1545 Route 206 South, Suite 302, Bedminster, NJ

Employee

Twitter

@MatinasBio

Next Earnings Date

2026-08-13

Latest SEC Filings

MTNB's Discussions on Twitter

Compare MTNB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MTNB Matinas Biopharma Holdings Inc	0.628	3.92M	1.10M	-11.23M	-6.61M	-2.025
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-26-20	Resumed	Piper Sandler	Overweight
Jan-27-20	Initiated	Piper Sandler	Overweight
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Jan-09-20	Initiated	Aegis Capital	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy

View All

Matinas Biopharma Holdings Inc Stock (MTNB) Latest News

Jul 01, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Jul 01, 2026

Jun 29, 2026

Price to earnings forward of Matinas Biopharma Holdings, Inc. – AMEX:MTNB - TradingView

Jun 29, 2026

Price to earnings forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView

Jun 29, 2026

Jun 28, 2026

Price to book forward of Matinas Biopharma Holdings, Inc. – AMEX:MTNB - TradingView

Jun 28, 2026

Price to sales forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView

Jun 28, 2026

Jun 27, 2026

Matinas BioPharma receives NYSE delisting plan extension - Investing.com UK

Jun 27, 2026

Jun 26, 2026

Matinas BioPharma Receives NYSE American Non-Compliance Notice, Granted Plan Period to Regain Listing Standards - Minichart

Jun 26, 2026

Matinas BioPharma (MTNB) Faces NYSE Equity Compliance Challenge - GuruFocus

Jun 26, 2026

Matinas BioPharma receives NYSE delisting plan extension By Investing.com - Investing.com Canada

Jun 26, 2026

Matinas BioPharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Jun 26, 2026

Matinas BioPharma (NYSE: MTNB) put on NYSE American equity compliance plan to avoid delisting - Stock Titan

Jun 26, 2026

Matinas BioPharma avoids delisting for now, gets 2027 NYSE plan period - Stock Titan

Jun 26, 2026

Matinas BioPharma Holdings, Inc. Actuals & Estimates (GETTEX:6LJ0) - TradingView

Jun 26, 2026